abstract |
An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation. |